Palvella Therapeutics (NASDAQ:PVLA) Shares Break Above 200-Day Moving Average After Insider Selling

Palvella Therapeutics, Inc. (NASDAQ:PVLA) shares passed above its 200-day moving average during trading on Monday after an insider bought additional shares in the company. The stock has a 200-day moving average of $125.77 and traded as high as $127.20. Palvella Therapeutics shares last traded at $126.23, with a volume of 110,504 shares traded.

Analyst Ratings Changes

PVLA has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Friday, September 25th. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. William Blair began coverage on shares of Palvella Therapeutics in a research note on Friday, October 16th. They issued an “outperform” rating on the stock. Finally, Raymond James Financial set a $226.00 target price on shares of Palvella Therapeutics in a research report on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Palvella Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $209.79.

Palvella Therapeutics Trading Up 0.9%

The business has a 50-day moving average price of $141.83 and a 200-day moving average price of $125.77. The firm has a market cap of $1.82 billion, a P/E ratio of -26.13 and a beta of -0.27.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.35). On average, equities analysts anticipate that Palvella Therapeutics, Inc. will post -6.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. KBC Group NV bought a new position in shares of Palvella Therapeutics in the 1st quarter worth $28,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Palvella Therapeutics during the 2nd quarter worth $35,000. Sterling Capital Management LLC boosted its position in Palvella Therapeutics by 907.7% during the third quarter. Sterling Capital Management LLC now owns 393 shares of the company’s stock valued at $54,000 after purchasing an additional 354 shares in the last quarter. Archer Investment Corp bought a new stake in Palvella Therapeutics during the second quarter valued at about $69,000. Finally, Quantbot Technologies LP bought a new stake in Palvella Therapeutics during the second quarter valued at about $71,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.